{{drugbox
| IUPAC_name = (S)-1-1pyrrolidine-2-carbonitrile
|synonyms = (2S)-1-{2-2acetyl}pyrrolidine-2-carbonitrile
| image = Vildagliptin Structural Formulae.png
| width = 140
| CAS_number = 274901-16-5
| ATC_prefix = A10
| ATC_suffix = BH02
| ATC_supplemental =
ATC: BD08 (with metformin)
| PubChem = 6918537
| DrugBank =
| C = 17 |H = 25 |N = 3 |O = 2
| molecular_weight = 303.399 g/mol
| bioavailability = 85%
| protein_bound = 9.3%
| metabolism = Mainly hydrolysis to inactive metabolite; CYP450 not appreciably involved
| elimination_half-life = 2 to 3 hours
| excretion = Renal
| pregnancy_category = Not recommended
| legal_UK = POM
| legal_status =
| routes_of_administration = Oral
}}
Vildagliptin (previously identified as LAF237, trade name Galvus) is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIPMentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35. PMID 8100523. by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Your changes have been saved.